ELTX news

Latest 2 stories · newest Jun 17, 2026

ELTX

Elicio Reports Complete Responses in Pancreatic Cancer Patients Receiving ELI-002 7P Plus Checkpoint Inhibition

Elicio Therapeutics reported that three metastatic pancreatic cancer patients achieved confirmed complete responses after receiving ELI-002 7P followed by nivolumab-based therapy, with responses persisting 8+ months. The company plans to initiate a Phase 1 study combining ELI-002 7P with checkpoint …

Regulatory Jun 17, 2026 sentiment +0.75 SEC filing ↗

ELTX

Elicio's ELI-002 7P misses Phase 2 primary endpoint but shows promise in R0 subset

Elicio Therapeutics reported that its AMPLIFY-7P Phase 2 study of ELI-002 7P failed to meet the primary disease-free survival endpoint in the intent-to-treat population for adjuvant pancreatic cancer, though post-hoc analysis showed benefit in completely resected (R0) patients representing 84% of th…

Regulatory Jun 15, 2026 sentiment -0.25 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same ELTX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/ELTX/newsSTART FREE